TIGIT blocking in HBsAg transgenic mice, whose adaptive immune system is tolerant to HBsAg, drives inflammation, chronic hepatitis and promotes HCC, along with the emergence of functional HBsAg-specific CTLs (141). Here, TIGIT is linked to hepatocellular carcinoma.